Under construction – not a live service
Sign in
Taking people in NorwayNo phase

Sporadic Degenerative Ataxia With Adult Onset: Natural History Study

Key facts

Where
Oslo, NorwaySee the site

Where in Norway

  • Oslo University HospitalOslo, NorwayContact: Chantal M.E. Tallaksen, MD, PhDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Ataxia Study Group
Trial code
NCT02701036
Record updated
29 June 2017
Original description
The key goals of SPORTAX-NHS is to compare the phenotype of multiple system atrophy of cerebellar type (MSA-C) and sporadic adult onset ataxia of unknown aetiology (SAOA) and to determine the rate of disease progression in both groups including determination of the factors that predict the development of MSA-C vs. SAOA, and at which time after onset of ataxia, a reliable distinction between both disorders is possible.Read full original descriptionShow less

Sporadic Degenerative Ataxia With Adult Onset: Natural History Study (SPORTAX-NHS)

The key goals of SPORTAX-NHS is to compare the phenotype of multiple system atrophy of cerebellar type (MSA-C) and sporadic adult onset ataxia of unknown aetiology (SAOA) and to determine the rate of disease progression in both groups including determination of the factors that predict the development of MSA-C vs. SAOA, and at which time after onset of ataxia, a reliable distinction between both disorders is possible.

The planned study will also allow to collect blood samples and other biomaterials from patients with sporadic ataxia, which will be useful for future genetic and biomarker studies.

Inclusion: Progressive ataxia; Disease onset after the age of 40 years; Informative and negative family history (no similar disorders in first- and second-degree relatives; parents older than 50 years, or, if not alive, age at death of more than 50 years, no consanguinity of parents).

Exclusion: no chronic intake of anticonvulsant drugs; No onset of ataxia in association with stroke, encephalitis, sepsis, hyperthermia or heat stroke; no other toxic causes; no malignancies; no insulin-dependent diabetes mellitus; Imaging exclusion criteria:; No evidence of multiple sclerosis, ischemia, hemorrhage or tumor of the posterior fossa; Negative molecular genetic testing for FRDA (only required if there is no cerebellar atrophy on MRI, SCA1, SCA2, SCA3, SCA6, FMR1 premutation (only required if prominent tremor, cognitive impairment and signal abnormality on T2/FLAIR images in the middle cerebellar peduncle); antineuronal antibodies negative (only required, if disease duration less than 3 years); absence of signal abnormalities on T2/FLAIR-images except abnormalities compatible with MSA; Laboratory exclusion criteria:; No established acquired cause of ataxia; Clinical exclusion criteria:; no chronic diarrhea; no unexplained visual loss; no alcohol abuse; no rapid progression (development of severe ataxia in less than 12 weeks); normal levels of vitamin B12; VDRL negative; normal thyreoid function.

ClinicalTrials.gov NCT02701036